argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

argenx Spotlights VYVGART Sales Surge, First Profitability Year and Expanding Pipeline at JPM Conference

(NASDAQ:ARGX) used its presentation at the 44th JPMorgan Healthcare Conference to highlight what CEO Tim Van Hauwermeiren ...
Opinion
Neurology AdvisorOpinion

Highlights From the 4th Annual Women in Neurology Conference

Women neurologists of various subspecialties and career stages gathered for the 4th Annual Women in Neurology Conference, hosted by the Women Neurologists Group.
BMJ

Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews

Objective To synthesise the evidence on the effects of physical activity on symptoms of depression, anxiety and psychological distress in adult populations. Design Umbrella review. Data sources Twelve ...